Official Title
Immune Response and Risk of Serious Infection to SARS-Cov2
Brief Summary

To date, nearly 2 million people, including at least 100,000 in France, have been infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). This infection is very heterogeneous in nature, ranging from asymptomatic forms to acute respiratory distress syndrome patterns in 6.1% of cases, leading to an estimated overall mortality of 5.2%. Apart from age, few risk factors for a pejorative evolution have been identified: arterial hypertension, diabetes, cardiovascular history, obesity and chronic respiratory pathology in particular. The median incubation period is 5 days and the median time between the appearance of the first symptoms and the onset of hypoxia requiring admission to intensive care is 7 to 12 days. The mechanisms involved in the occurrence of these secondary worsening patterns are unclear. One hypothesis is that it is related to an inappropriate inflammatory response rather than a direct cytopathic effect of the virus. The objective of this study is to measure the intensity of the T lymphocyte response in patients hospitalized for Cov2 SARS infection in order to determine whether the intensity of the response is associated with worsening of symptoms.

Unknown status
SARS Cov2, Immune Response

Biological: Blood sample collection

Additional blood volumes taken during a routine care blood test:
1 dry tube 5 mL for isolation and freezing of serum
1 x 5 mL EDTA tube to isolate and freeze plasma
8 heparinized 6 mL tubes for flow cytometry study

Eligibility Criteria

Inclusion Criteria:

- Person having given his or her non-opposition

- Patient hospitalized with an SARS-Cov2 infection proven by virological sampling
(nasopharyngeal or sputum PCR) less than 8 days old.

Exclusion Criteria:

- Person subject to a legal protection measure (curatorship, guardianship)

- Person subject to a safeguard measure of justice

- Pregnant, parturient or breastfeeding woman

- Major incapable or incapable of giving consent

- Minor

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Chu Dijon Bourogne
Dijon, France

Investigator: Thibault GHESQUIERE
Contact: 0380293857
thibault.ghesquiere@chu-dijon.fr

Contacts

Thibault GHESQUIERE
0380293857 - +33
thibault.squiere@chu-dijon.fr

Centre Hospitalier Universitaire Dijon
NCT Number
MeSH Terms
Infections